Announcements Trials
Browse Landscape

Phase

Phase 1 2

Status

Withdrawn 1Unknown 1

Sponsor Class

NIH 1INDUSTRY 1

Study Type

Interventional 2

Sponsor

Cancer Type

CNS 7Sarcoma 3Breast 3Thoracic 2Other solid neoplasm 2Lymphoid 2Head & Neck 2Gynecologic 2Genitourinary 2Gastrointestinal 2Dermatologic 2Tumor-Agnostic 1Plasma cell 1

Conditions

Urinary Bladder Neoplasms 1Metastatic Castration-resistant Prostate Cancer (mCRPC) 1Colorectal Neoplasms 1Breast Neoplasms 1

Interventions

Docetaxel 409pembrolizumab 332Prednisone 290enzalutamide 285Gemcitabine 274Radiotherapy 270Magnetic Resonance Spectroscopy 269Nivolumab 253Abiraterone Acetate 218Cisplatin 212Leuprolide 195Radiosurgery 192Sunitinib 188Carboplatin 161Androgen Antagonists 156bicalutamide 152Specimen Handling 149Goserelin 149Ipilimumab 131Paclitaxel 126acetyl-2-naphthylalanyl-3-chlorophenylalanyl-1-oxohexadecyl-seryl-4-aminophenylalanyl(hydroorotyl)-4-aminophenylalanyl(carbamoyl)-leucyl-ILys-prolyl-alaninamide 122apalutamide 118Cyclophosphamide 117Bevacizumab 116Sorafenib 114Everolimus 111abiraterone 108cabozantinib 105atezolizumab 105Biopsy 101

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
efineptakin alfa × Genitourinary × Clear all
NCT06344715 2024-04-03

Phase 1 Study Evaluating Safety and Tolerability of SL-T10, GX-I7, and Pembrolizumab Triple Combination in mCRPC.

SL VAXiGEN

Phase 1 Unknown
78 enrolled
Genitourinary

Metastatic Castration-resistant Prostate Cancer (mCRPC)

NCT04054752 2023-11-02

Vaccine Response With NT-I7

National Institutes of Health Clinical Center (CC)

Phase 1 Withdrawn
BreastGastrointestinalGenitourinary

Urinary Bladder Neoplasms, Breast Neoplasms, Colorectal Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡